Claudia Isela Avitia-Domínguez

Dr. Claudia Isela Avitia-Domínguez


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JGJuan Gayosso-De-Lucio
Juan Gayosso-De-Lucio
MTMartin Torres-Valencia
Martin Torres-Valencia
ARArturo Rojo-Domínguez
Arturo Rojo-Domínguez
HNHugo Nájera
Hugo Nájera
BABeatriz Aguirre-López
Beatriz Aguirre-López
ATAlfredo Téllez-Valencia
Alfredo Téllez-Valencia

14 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MAMara Ibeth Campos Almazán
Mara Ibeth Campos Almazán
AHAlicia Hernández-Campos
Alicia Hernández-Campos
RCRafael Castillo
Rafael Castillo
ESErick Sierra-Campos
Erick Sierra-Campos
MVMónica Andrea Valdez-Solana
Mónica Andrea Valdez-Solana
AVAlfredo Téllez Valencia
Alfredo Téllez Valencia
Protein tyrosine phosphatase 1B (PTP1B) dephosphorylates phosphotyrosine residues and is an important regulator of several signaling pathways, such as insulin, leptin, and the ErbB signaling network, among others. Therefore, this enzyme is considered an attractive target to design new drugs against type 2 diabetes, obesity, and cancer. To date, a wide variety of PTP1B inhibitors that have been developed by experimental and computational approaches. In this review, we summarize the achievements with respect to PTP1B inhibitors discovered by applying computer-assisted drug design methodologies (virtual screening, molecular docking, pharmacophore modeling, and quantitative structure–activity relationships (QSAR)) as the principal strategy, in cooperation with experimental approaches, covering articles published from the beginning of the century until the time this review was submitted, with a focus on studies conducted with the aim of discovering new drugs against type 2 diabetes. This review encourages the use of computational techniques and includes helpful information that increases the knowledge generated to date about PTP1B inhibition, with a positive impact on the route toward obtaining a new drug against type 2 diabetes with PTP1B as a molecular target.

5 August 2017 in Foods
Verified
Journal Article
Open access
PDF file
MSMaría Alejandra Sánchez-Muñoz
María Alejandra Sánchez-Muñoz
MVMónica Andrea Valdez-Solana
Mónica Andrea Valdez-Solana
CAClaudia Isela Avitia-Domínguez
Claudia Isela Avitia-Domínguez
PRPatricia Ramírez-Baca
Patricia Ramírez-Baca
MCMaría Guadalupe Candelas Cadillo
María Guadalupe Candelas Cadillo
ESErick Sierra-Campos
Erick Sierra-Campos
In this study, the potential use of Moringa oleifera as a clotting agent of different types of milk (whole, skim, and soy milk) was investigated. M. oleifera seed extract showed high milk-clotting activity followed by flower extract. Specific clotting activity of seed extract was 200 times higher than that of flower extract. Seed extract is composed by four main protein bands (43.6, 32.2, 19.4, and 16.3 kDa). Caseinolytic activity assessed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and tyrosine quantification, showed a high extent of casein degradation using M. oleifera seed extract. Milk soy cheese was soft and creamy, while skim milk cheese was hard and crumbly. According to these results, it is concluded that seed extract of M. oleifera generates suitable milk clotting activity for cheesemaking. To our knowledge, this study is the first to report comparative data of M. oleifera milk clotting activity between different types of soy milk.

1 March 2018 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
MSMaría Alejandra Sánchez-Muñoz
María Alejandra Sánchez-Muñoz
MVMónica Andrea Valdez-Solana
Mónica Andrea Valdez-Solana
MAMara Ibeth Campos Almazán
Mara Ibeth Campos Almazán
ÓFÓscar Flores-Herrera
Óscar Flores-Herrera
MEMercedes Esparza-Perusquía
Mercedes Esparza-Perusquía
ESErick Sierra-Campos
Erick Sierra-Campos
The increasing prevalence of diabetes continues to be a major health issue worldwide. Alteration of mitochondrial electron transport chain is a recognized hallmark of the diabetic-associated decline in liver bioenergetics; however, the molecular events involved are only poorly understood.Moringa oleiferais used for the treatment of diabetes. However, its role on mitochondrial functionality is not yet established. This study was aimed to evaluate the effect ofM. oleiferaextract on supercomplex formation, ATPase activity, ROS production, GSH levels, lipid peroxidation, and protein carbonylation. The levels of lipid peroxidation and protein carbonylation were increased in diabetic group. However, the levels were decreased inMoringa-treated diabetic rats. Analysis of in-gel activity showed an increase in all complex activities in the diabetic group, but spectrophotometric determinations of complex II and IV activities were unaffected in this treatment. However, we found an oxygen consumption abolition through complex I-III-IV pathway in the diabetic group treated withMoringa. While respiration with succinate feeding into complex II-III-IV was increased in the diabetic group. These findings suggest that hyperglycemia modifies oxygen consumption, supercomplexes formation, and increases ROS levels in mitochondria from the liver of STZ-diabetic rats, whereasM. oleiferamay have a protective role against some alterations.

8 September 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
ESErick Sierra-Campos
Erick Sierra-Campos
MVMónica Valdez-Solana
Mónica Valdez-Solana
CAClaudia Isela Avitia-Domínguez
Claudia Isela Avitia-Domínguez
MCMara Campos-Almazán
Mara Campos-Almazán
IFismael flores
ismael flores
AVAlfredo Téllez Valencia
Alfredo Téllez Valencia
In our study, we aimed to evaluate the effects of Moringa oleifera leaves extract on rat paraoxonase 1 (rPON1) and catalase (rCAT) activities in alloxan-induced diabetic rats. Our study included three groups; group C (control, n = 5); group D (diabetic, n = 5); and group DM (M. oleifera extract-supplemented diabetic rats, n = 5). Daily oral administration of M. oleifera extract at 200 mg/kg doses produced an increase in endogenous antioxidants. Serum rPON1 (lactonase) and liver cytosol catalase activities were determined by a spectrophotometric assay using progress curve analysis. We found a decrease in the Vm value of rPON1 in diabetic rats, but dihydrocoumarin (DHC) affinity (Km) was slightly increased. The value of Vm for the DM group was found to be reduced approximately by a factor of 3 compared with those obtained for group C, whereas Km was largely changed (96 times). Catalase activity was significantly higher in the DM group. These data suggest that the activation of rPON1 and rCAT activities by M. oleifera extracts may be mediated via the effect of the specific flavonoids on the enzyme structure. In addition, through molecular blind docking analysis, rPON1 was found to have two binding sites for flavonoids. In contrast, flavonoids bound at four sites in rCAT. In conclusion, the data suggest that compounds from M. oleifera leaves extract were able to influence the catalytic activities of both enzymes to compensate for the changes provoked by diabetes in rats.

10 April 2014 in Molecules
Verified
Journal Article
Open access
PDF file
CAClaudia Isela Avitia-Domínguez
Claudia Isela Avitia-Domínguez
ESErick Sierra-Campos
Erick Sierra-Campos
JSJosé M. Salas-Pacheco
José M. Salas-Pacheco
HNHugo Nájera
Hugo Nájera
ARArturo Rojo-Domínguez
Arturo Rojo-Domínguez
AVAlfredo Téllez Valencia
Alfredo Téllez Valencia
Methicillin-resistant Staphylococcus auerus (MRSA) strains are having a major impact worldwide, and due to their resistance to all β-lactams, an urgent need for new drugs is emerging. In this regard, the shikimate pathway is considered to be one of the metabolic features of bacteria and is absent in humans. Therefore enzymes involved in this route, such as shikimate dehydrogenase (SDH), are considered excellent targets for discovery of novel antibacterial drugs. In this study, the SDH from MRSA (SaSDH) was characterized. The results showed that the enzyme is a monomer with a molecular weight of 29 kDa, an optimum temperature of 65 °C, and a maximal pH range of 9–11 for its activity. Kinetic studies revealed that SDH showed Michaelis-Menten kinetics toward both substrates (shikimate and NADP+). Initial velocity analysis suggested that SaSDH catalysis followed a sequential random mechanism. Additionally, a tridimensional model of SaSDH was obtained by homology modeling and validated. Through virtual screening three inhibitors of SaSDH were found (compounds 238, 766 and 894) and their inhibition constants and mechanism were obtained. Flexible docking studies revealed that these molecules make interactions with catalytic residues. The data of this study could serve as starting point in the search of new chemotherapeutic agents against MRSA.